开云app官网登录入口网页版-官方正版

#Xpovio#

8篇内容 | 921人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1685450, encodeId=dbfc1685450e7, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, objectTitle=The Lancet：核出口抑制剂XPOVIO显著延长复发或难治性多发性骨髓瘤患者的无进展生存期, objectType=article, longId=203482, objectId=6ec6203482bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ec6203482bb, replyNumber=0, likeNumber=67, createdTime=2021-10-01, rootId=0, userName=chshh86, userId=516628191616, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ec6203482bb, moduleTitle=The Lancet：核出口抑制剂XPOVIO显著延长复发或难治性多发性骨髓瘤患者的无进展生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6ec6203482bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685449, encodeId=80da168544971, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, objectTitle=FDA批准治疗复发或难治性大B细胞淋巴瘤患者的口服药物：核出口抑制剂XPOVIO, objectType=article, longId=196393, objectId=d7b919639342, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7b919639342, replyNumber=0, likeNumber=84, createdTime=2021-04-20, rootId=0, userName=chshh86, userId=516628191616, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7b919639342, moduleTitle=FDA批准治疗复发或难治性大B细胞淋巴瘤患者的口服药物：核出口抑制剂XPOVIO, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d7b919639342)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685451, encodeId=b74b1685451f9, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, objectTitle=FDA批准Karyopharm的Xpovio（selinexor）用于治疗多发性骨髓瘤, objectType=article, longId=204714, objectId=6286204e1417, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6286204e1417, replyNumber=0, likeNumber=90, createdTime=2021-07-09, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6286204e1417, moduleTitle=FDA批准Karyopharm的Xpovio（selinexor）用于治疗多发性骨髓瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6286204e1417)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685448, encodeId=37b2168544865, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, objectTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, objectType=article, longId=189451, objectId=9d821894518e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d821894518e, replyNumber=0, likeNumber=75, createdTime=2020-11-08, rootId=0, userName=chshh86, userId=516628191616, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d821894518e, moduleTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9d821894518e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685445, encodeId=6a4916854455c, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, objectTitle=NEJM：XPOVIO（Selinexor）治疗难治性多发性骨髓瘤的IIb期STORM研究, objectType=article, longId=178110, objectId=262c1e81109b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=262c1e81109b, replyNumber=0, likeNumber=60, createdTime=2020-05-04, rootId=0, userName=chshh86, userId=516628191616, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=262c1e81109b, moduleTitle=NEJM：XPOVIO（Selinexor）治疗难治性多发性骨髓瘤的IIb期STORM研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=262c1e81109b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685447, encodeId=eb6d168544e7c, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, objectTitle=FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请，用于治疗复发或难治的弥漫性大B细胞淋巴瘤, objectType=article, longId=188486, objectId=9acb18848624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9acb18848624, replyNumber=0, likeNumber=67, createdTime=2020-08-16, rootId=0, userName=chshh86, userId=516628191616, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9acb18848624, moduleTitle=FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请，用于治疗复发或难治的弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9acb18848624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685446, encodeId=ca281685446de, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, objectTitle=第17届国际骨髓瘤研讨会（IMW）：XPOVIO（Selinexor）的全新临床数据将被披露, objectType=article, longId=179536, objectId=b7571e9536db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7571e9536db, replyNumber=0, likeNumber=81, createdTime=2019-11-30, rootId=0, userName=chshh86, userId=516628191616, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7571e9536db, moduleTitle=第17届国际骨髓瘤研讨会（IMW）：XPOVIO（Selinexor）的全新临床数据将被披露, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b7571e9536db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685444, encodeId=bf78168544454, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, objectTitle=FDA批准Karyopharm的核输出抑制剂Xpovio用于治疗复发或难治的多发性骨髓瘤, objectType=article, longId=174802, objectId=d82e1e480215, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d82e1e480215, replyNumber=0, likeNumber=120, createdTime=2020-04-27, rootId=0, userName=chshh86, userId=516628191616, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d82e1e480215, moduleTitle=FDA批准Karyopharm的核输出抑制剂Xpovio用于治疗复发或难治的多发性骨髓瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d82e1e480215)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

Xpovio

2020-05-29

chshh86 (审核中...)

前往app查看评论内容

#Xpovio#

The Lancet：核出口抑制剂XPOVIO显著延长复发或难治性多发性骨髓瘤患者的无进展生存期

2021-10-01

chshh86 (审核中...)

前往app查看评论内容

#Xpovio#

FDA批准治疗复发或难治性大B细胞淋巴瘤患者的口服药物：核出口抑制剂XPOVIO

2021-04-20

医者仁心 (审核中...)

前往app查看评论内容

#Xpovio#

FDA批准Karyopharm的Xpovio（selinexor）用于治疗多发性骨髓瘤

2021-07-09

chshh86 (审核中...)

前往app查看评论内容

#Xpovio#

Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点

2020-11-08

chshh86 (审核中...)

前往app查看评论内容

#Xpovio#

NEJM：XPOVIO（Selinexor）治疗难治性多发性骨髓瘤的IIb期STORM研究

2020-05-04

chshh86 (审核中...)

前往app查看评论内容

#Xpovio#

FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请，用于治疗复发或难治的弥漫性大B细胞淋巴瘤

2020-08-16

chshh86 (审核中...)

前往app查看评论内容

#Xpovio#

第17届国际骨髓瘤研讨会（IMW）：XPOVIO（Selinexor）的全新临床数据将被披露

2019-11-30

chshh86 (审核中...)

前往app查看评论内容

#Xpovio#

FDA批准Karyopharm的核输出抑制剂Xpovio用于治疗复发或难治的多发性骨髓瘤

2020-04-27

科室
- - 订阅+
  - 更多科室
工具
服务